PHAXIAM TX news, videos and press releases - Page 2
For more news please use our advanced search feature.
PHAXIAM TX - More news...
PHAXIAM TX - More news...
- ERYTECH announces that Akkadian has initiated proceedings to postpone the vote on the merger with Pherecydes
- ERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 23, 2023
- Monthly information related to total number of voting rights and shares composing the share capital _April 30, 2023
- Monthly information related to total number of voting rights and shares composing the share capital _March 31, 2023
- ERYTECH Provides Business and Financial Update for the Fourth Quarter and Full Year 2022
- Monthly information related to total number of voting rights and shares composing the share capital _January 31, 2023
- Monthly information related to total number of voting rights and shares composing the share capital _December 31, 2022
- Monthly information related to total number of voting rights and shares composing the share capital _October 30, 2022
- ERYTECH Announces Receipt of Nasdaq Notice
- Monthly information related to total number of voting rights and shares composing the share capital _July 31, 2022
- ERYTECH Provides Regulatory Update
- Report – ERYTECH’s Combined Shareholders’ Meeting On June 24, 2022
- Monthly information related to total number of voting rights and shares composing the share capital _May 31, 2022.
- ERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 24, 2022
- ERYTECH Announces Filing of 2021 Universal Registration Document and 2021 Annual Report on Form 20-F, as well as its 2022 financial calendar
- ERYTECH Sells U.S. Manufacturing Facility and Enters Long-Term Supply Agreement with Catalent
- ERYTECH Announces Publication of Positive Results from Eryaspase Phase 2 Trial in Hypersensitive ALL in the British Journal of Haematology
- ERYTECH to Present Novel Vesiculation Approach at the 24th Meeting of the European Red Cell Society
- ERYTECH to Participate in the Upcoming April Investor Conferences
- ERYTECH Provides Business and Financial Update for the Fourth Quarter and Full Year 2021
- ERYTECH Expands Patent Portfolio for the Treatment of Rare Metabolic Diseases
- ERYTECH Announces Presentation of Results of Two Clinical Trials of Eryaspase in Pancreatic Cancer at ASCO GI
- Monthly information related to total number of voting rights and shares composing the share capital – December 31, 2021
- ERYTECH to Participate in the Upcoming January Virtual Investor Conferences
- ERYTECH Announces $7.85 Million Registered Direct Offering
- ERYTECH Announces Presentation of Results of Expanded Access Program in ALL at 2021 ASH Annual Meeting and Acceptance of Two Abstracts at ASCO GI
- Monthly information related to total number of voting rights and shares composing the share capital – November 30, 2021
- ERYTECH Provides Business and Financial Update for the Third Quarter of 2021
- ERYTECH Announces Publication of a Paper on Red-Blood Cell Characterization in High Impact Peer Reviewed Journal
- ERYTECH to Present at the 12th Annual Jefferies Global London Healthcare Conference
